- Home
- WOK vs SLS Comparison
WOK vs SLS Comparison
Compare WOK & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WOK
- SLS
- Stock Information
- Founded
- WOK 2002
- SLS 2012
- Country
- WOK China
- SLS United States
- Employees
- WOK N/A
- SLS N/A
- Industry
- WOK
- SLS Biotechnology: Pharmaceutical Preparations
- Sector
- WOK
- SLS Health Care
- Exchange
- WOK NYSE
- SLS Nasdaq
- Market Cap
- WOK 5.8M
- SLS 89.6M
- IPO Year
- WOK 2024
- SLS N/A
- Fundamental
- Price
- WOK $0.41
- SLS $1.40
- Analyst Decision
- WOK
- SLS
- Analyst Count
- WOK 0
- SLS 0
- Target Price
- WOK N/A
- SLS N/A
- AVG Volume (30 Days)
- WOK 220.8K
- SLS 1.3M
- Earning Date
- WOK 02-03-2025
- SLS 05-13-2025
- Dividend Yield
- WOK N/A
- SLS N/A
- EPS Growth
- WOK N/A
- SLS N/A
- EPS
- WOK N/A
- SLS N/A
- Revenue
- WOK $11,506,440.00
- SLS N/A
- Revenue This Year
- WOK N/A
- SLS N/A
- Revenue Next Year
- WOK N/A
- SLS N/A
- P/E Ratio
- WOK N/A
- SLS N/A
- Revenue Growth
- WOK N/A
- SLS N/A
- 52 Week Low
- WOK $0.36
- SLS $0.77
- 52 Week High
- WOK $8.45
- SLS $1.84
- Technical
- Relative Strength Index (RSI)
- WOK N/A
- SLS 72.02
- Support Level
- WOK N/A
- SLS $1.29
- Resistance Level
- WOK N/A
- SLS $1.38
- Average True Range (ATR)
- WOK 0.00
- SLS 0.09
- MACD
- WOK 0.00
- SLS 0.03
- Stochastic Oscillator
- WOK 0.00
- SLS 86.54
About WOK WORK MEDICAL TECHNOLOGY GROUP LTD
WORK Medical Technology Group Ltd is engaged in manufacturing and selling medical consumables through its wholly owned subsidiaries in the People's Republic of China. The Company's main products include medical face masks, tourniquets, airways, breathing circuits, intubation accessories, anesthesia kits, oxygen masks, suction sets, laryngoscope blades, KN95 masks, and other disposable medical devices, as well as medical equipment.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.